HIV Prevention Trials Network (HPTN)

HPTN studies evaluate innovative strategies in populations and geographical regions that bear a disproportionate burden of risk including cisgender women, adolescents and young people, cisgender men who have sex with men (MSM), transgender people, and people who use substances at sites located in Asia, Europe, sub-Saharan Africa, and North and South America. Since its inception in 1999, the HPTN has had a long history of successfully conceptualizing, designing, and implementing, complex clinical research studies with a focus on biomedical interventions and integrated strategies to prevent HIV acquisition and transmission with more than 65 clinical research sites (CRSs) globally. The HPTN has long-standing partnerships with pharmaceutical companies, academic researchers worldwide, the Bill and Melinda Gates Foundation and several other organizations. In addition, the HPTN has forged collaborations to develop integrated strategies with PEPFAR, the Centers for Disease Control and Prevention (CDC) and both ministries and departments of health in several countries. HPTN receives its funding from three U.S. National Institutes of Health (NIH): the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health, and the National Institute on Drug Abuse.